Robert Goldman, PhD

Long-term Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: The aim of this post-hoc analysis was to evaluate the long-term efficacy of lurasidone in antipsychotic-naïve adolescents with schizophrenia.

Robert Goldman , PhD;

Christoph U. Correll , MD;

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Jay Hsu , PhD;

10/08/2020

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: Analysis of a 2-year, Open-label Extension Study

Objective: To obtain long-term data on the safety and effectiveness of lurasidone in adolescents with schizophrenia Methods: Adolescents (13-17 years) who completed 6 weeks of double-bli...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

03/01/2019

Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Children and Adolescents with Bipolar Depression

Background: The aim of these analyses was to assess the effect of lurasidone on manic symptoms and treatment-emergent (TE) mania in pediatric patients with bipolar depression.

Michael Tocco , PhD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Effect of Lurasidone on Cognition in Children and Adolescents With Bipolar Depression: Interim Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the long-term effects of lurasidone on cognition in children and adolescents with bipolar depression.

Ling Deng , PhD;

Katherine Burdick , PhD;

Michael Tocco , PhD;

Antony Loebel , MD;

Robert Goldman , PhD;

03/01/2019

Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to be Helped or Harmed (LHH) Analyses

Background: Four medications are FDA approved for acute bipolar depression: lurasidone (LUR), cariprazine (CAR), quetiapine IR & XR (QUE), and olanzapine-fluoxetine combination (OFC)....

Leslie Citrome , MD;

Robert Goldman , PhD;

Andrei Pikalov , MD, PhD;

Courtney Zeni , PhD;

10/08/2020

Effect of Lurasidone on Cognition in Adolescents With Schizophrenia: Analysis of a 2-year Open-label Extension Study

Objective: To evaluate the short and long-term effects of lurasidone on cognitive performance in adolescents with schizophrenia.

Antony Loebel , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Philip Harvey , PhD;

Josephine Cucchiaro , PhD;

Michael Tocco , PhD;

03/01/2019

Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: Few studies have prospectively evaluated short- or long-term antipsychotic efficacy in treatment-naïve (vs. previously treated) first-episode schizophrenia. The aim of this po...

Robert Goldman , PhD;

Christoph U. Correll , MD;

Michael Tocco , PhD;

Jay Hsu , PhD;

11/22/2019

Dasotraline for Treatment of Adults With Binge-eating Disorder: Effect on Behavioral Outcomes - Week 2

Objective: To evaluate the efficacy of dasotraline in the treatment of secondary behavioral and psychological outcomes in patients with Binge-eating disorder (BED).

Antony Loebel , MD;

Robert Goldman , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Brad Navia , MD, PhD;

James Hudson , MD;

Susan McElroy , MD;

Ling Deng , PhD;

03/01/2019

Safety and Effectiveness of Lurasidone in Children and Adolescents With Bipolar Depression: Results From a 2-Year Open-label Extension Study

Objective: The aim of the current study was to evaluate the long-term safety and effectiveness of lurasidone in pediatric bipolar depression. Method: Patients 10-17 years with bipolar I ...

Andrei Pikalov , MD, PhD;

Michael Tocco , PhD;

Melissa DelBello , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

11/22/2019

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Justine Kent , MD;

Antony Loebel , MD;

10/08/2020